Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

BUY
$191.17 - $325.63 $2.07 Million - $3.52 Million
10,810 Added 126.64%
19,346 $6.3 Million
Q4 2023

Feb 13, 2024

BUY
$160.99 - $215.69 $1.29 Million - $1.73 Million
8,012 Added 1529.01%
8,536 $1.63 Million
Q3 2023

Nov 14, 2023

BUY
$194.33 - $283.97 $101,828 - $148,800
524 New
524 $104,000
Q1 2023

May 12, 2023

SELL
$175.41 - $217.92 $2.8 Million - $3.47 Million
-15,939 Reduced 50.59%
15,570 $3.38 Million
Q4 2022

Feb 24, 2023

BUY
$204.38 - $296.82 $3.09 Million - $4.49 Million
15,122 Added 92.28%
31,509 $6.48 Million
Q4 2022

Feb 13, 2023

SELL
$204.38 - $296.82 $263,241 - $382,304
-1,288 Reduced 7.29%
16,387 $3.37 Million
Q3 2022

Nov 14, 2022

SELL
$195.21 - $310.53 $856,386 - $1.36 Million
-4,387 Reduced 19.88%
17,675 $5.12 Million
Q2 2022

Aug 12, 2022

SELL
$115.91 - $214.48 $1 Million - $1.85 Million
-8,640 Reduced 28.14%
22,062 $4.3 Million
Q1 2022

May 13, 2022

SELL
$127.96 - $207.36 $266,924 - $432,552
-2,086 Reduced 6.36%
30,702 $6.37 Million
Q4 2021

Feb 14, 2022

SELL
$165.13 - $241.83 $247,695 - $362,745
-1,500 Reduced 4.37%
32,788 $5.85 Million
Q3 2021

Nov 12, 2021

BUY
$163.99 - $235.57 $5.62 Million - $8.08 Million
34,288 New
34,288 $7.06 Million
Q2 2021

Aug 13, 2021

SELL
$131.45 - $201.49 $4.9 Million - $7.51 Million
-37,296 Closed
0 $0
Q1 2021

May 14, 2021

BUY
$92.73 - $142.05 $473,479 - $725,307
5,106 Added 15.86%
37,296 $4.86 Million
Q4 2020

Feb 12, 2021

SELL
$67.44 - $103.72 $82,344 - $126,642
-1,221 Reduced 3.65%
32,190 $3.34 Million
Q3 2020

Nov 12, 2020

BUY
$42.79 - $75.8 $144,202 - $255,446
3,370 Added 11.22%
33,411 $2.53 Million
Q2 2020

Aug 13, 2020

BUY
$27.25 - $47.53 $818,617 - $1.43 Million
30,041 New
30,041 $1.42 Million

Others Institutions Holding SWAV

About Shockwave Medical, Inc.


  • Ticker SWAV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 35,927,100
  • Description
  • ShockWave Medical, Inc., a medical device company, engages in developing and commercializing intravascular lithotripsy technology for the treatment of calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases worldwide. The company offers M5 catheters for treating above-the-knee peripheral artery disease ...
More about SWAV
Track This Portfolio

Track Natixis Portfolio

Follow Natixis and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Natixis, based on Form 13F filings with the SEC.

News

Stay updated on Natixis with notifications on news.